Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy (2017)
Source: European Journal of Pharmaceutics and Biopharmaceutics. Unidade: IQSC
Subjects: BIOLOGIA CELULAR, PROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Natália N. et al. Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, v. 119, p. 271-282, 2017Tradução . . Disponível em: http://dx.doi.org/10.1016/j.ejpb.2017.06.028. Acesso em: 26 mar. 2023.APA
Ferreira, N. N., Ferreira, L. M. N., Miranda-Gonçalves, V., Reis, R. M., Seraphim, T. V., Borges, J. C., et al. (2017). Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 119, 271-282. doi:10.1016/j.ejpb.2017.06.028NLM
Ferreira NN, Ferreira LMN, Miranda-Gonçalves V, Reis RM, Seraphim TV, Borges JC, Baltazar F, Gremiao MPD. Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2017 ; 119 271-282.[citado 2023 mar. 26 ] Available from: http://dx.doi.org/10.1016/j.ejpb.2017.06.028Vancouver
Ferreira NN, Ferreira LMN, Miranda-Gonçalves V, Reis RM, Seraphim TV, Borges JC, Baltazar F, Gremiao MPD. Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2017 ; 119 271-282.[citado 2023 mar. 26 ] Available from: http://dx.doi.org/10.1016/j.ejpb.2017.06.028
